CSL’s ‘big’ post-heart attack drug fails in Phase III trial
Clinical Trials Arena,
CSL’s post-MI drug failed to meet its primary endpoint of reducing the risk of major adverse cardiovascular events.
CSL’s post-MI drug failed to meet its primary endpoint of reducing the risk of major adverse cardiovascular events.
According to the American Heart Association, a heart attack happens about every 40 seconds in the United States.
A widowmaker heart attack is a type of heart attack that occurs when a blood clot or plaque deposit completely blocks the left…
A widowmaker heart attack is a type of heart attack that occurs when a blood clot or plaque deposit completely blocks the left…